Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy

Current Opinion in Rheumatology

Volumn 26, Issue 3, 2014, Pages 334-340

  Bermas, Bonnie L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

disease modifying antirheumatic drugs; glucocorticoids; nonsteroidal anti inflammatory drugs; pregnancy; rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; BETAMETHASONE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE INHIBITOR; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TOFACITINIB; ANTIRHEUMATIC AGENT;

CLEFT PALATE; CONCEPTION; DUCTUS ARTERIOSUS; FERTILITY; FIRST TRIMESTER PREGNANCY; HUMAN; MATERNAL HYPERTENSION; MEMBRANE RUPTURE; NONHUMAN; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREMATURITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; FEMALE; FETOMATERNAL TRANSFUSION; MATERNAL CARE; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FERTILITY; GLUCOCORTICOIDS; HUMANS; MATERNAL-FETAL EXCHANGE; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84897556167     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000054     Document Type: Review

References (69)

1. de Man YA, Dolhain RJ, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008; 59:1241-1248.
2. Kalter H, Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). N Engl J Med 1983; 308:424-431.
3. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369:307-318.
4. Barbhaiya M, Bermas BL, Taylor TH, et al. Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy. Clin Immunol 2013; 149:225-235.
5. Slone D, Siskind V, Heinonen OP, et al. Aspirin and congenital malformations. Lancet 1976; 1:1373-1375.
6. Hertz-Picciotto I,Hopenhayn-Rich C, Golub M,Hooper K. The risks and benefits of taking aspirin during pregnancy. Epidemiol Rev 1990; 12:108-148.
7. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318-1323.
8. Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of preeclampsia in high-risk women: a randomised placebo-controlled predo trial and a meta-analysis of randomised trials. BJOG 2013; 120:64-74.
9. Cook JC, Jacobson CF, Gao F, et al. Analysis of the nonsteroidal antiinflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2003; 68:5-26.
10. van Gelder MM, Roeleveld N, Nordeng H. Exposure to nonsteroidal antiinflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One 2011; 6:e22174.
11. Daniel S, Matok I, Gorodischer R, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 2012; 39:2163-2169.
12. Schoenfeld A, Bar Y, Merlob P, Ovadia Y. NSAIDS: maternal and fetal considerations. Am J Reprod Immunol 1992; 28:141-147.
13. Van Marter LJ, Hernandez-Diaz S, Werler MM, et al. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics 2013; 131:79-87.
14. Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208.
15. Pall M, Friden BE, Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323-1328.
16. Nakhai-Pour HR, Broy P, Sheehy O, Berard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011; 183:1713-1720.
17. Edwards DR, Aldridge T, Baird DD, et al. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol 2012; 120:113-122.
18. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977; 127:264-267.
19. Reinisch JM, Simon NG, Gandelman R. Prenatal exposure to prednisone permanently alters fighting behavior of female mice. Pharmacol Biochem Behav 1980; 12:213-216.
20. Pinsky L, Digeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science 1965; 147:402-403.
21. Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975; 233:804-807.
22. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385-392.
23. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999; 86:242-244.
24. Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197:585.
25. Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93-101.
26. Han AR, Ahn H, Vu P, et al. Obstetrical outcomeof anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility. Am J Reprod Immunol 2012; 68:418-427.
27. Guller S, Kong L, Wozniak R, Lockwood CJ. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab 1995; 80:2244-2250.
28. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8:209.
29. Ullberg S, Lindquist NG, Sjostrand SE. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature 1970; 227:1257-1258.
30. Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol 1964; 80:407-412.
31. Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55:50-56.
32. KhamashtaMA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: The British experience. Lupus 1996; 5 (Suppl 1):S65-S66.
33. Costedoat-Chalumeau N, Amoura Z, Huong DL, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: review of the literature. Autoimmun Rev 2005; 4:111-115.
34. Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002; 29:700-706.
35. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005; 25:86-89.
36. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011; 38: 2504-2508.
37. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/era-edta) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771-1782.
38. Jarnerot G, Into-Malmberg MB, Esbjorner E. Placental transefer of sulfasalazine an d sulfapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16:693-697.
39. Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 1988; 318:1128.
40. Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80:72-76.
41. Rahimi R, NIkfor S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25:271-275.
42. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608-1614.
43. Chatzinoff M, Guarino JM, Corson SL, et al. Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. Dig Dis Sci 1988; 33:108-110.
44. Skalko RG, Gold MP. Teratogenicity of methotrexate in mice. Teratology 1974; 9:159-163.
45. Hoppe DE, Bekkar BE, Nager CW. Single-dose systemic methotrexate for the treatment of persistent ectopic pregnancy after conservative surgery. Obstet Gynecol 1994; 83:51-54.
46. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998; 57:51-55.
47. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993; 47:553-559.
48. Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92:551-563.
49. Donnenfeld AE, Pastuszak A, Noah JS, et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994; 49:79-81.
50. Brent RL. Teratogen update: Reproductive risks of leflunomide (arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001; 63:106-112.
51. Neville CE, McNally J. Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford) 2007; 46:1506.
52. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30:241-246.
53. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62:1494-1503.
54. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012; 64:2085-2094.
55. Szabo KT, DiFebbo ME, Phelan DG. The effects of gold-containing compounds on pregnant rabbits and their fetuses. Vet Pathol 1978; 15 (Suppl 5):97-102.
56. Fuchs U, Lippert TH. Gold therapy and pregnancy. Dtsch Med Wochenschr 1986; 111:31-34.
57. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115:1100-1106.
58. DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 1984; 105:625-628.
59. Ostrer H, Stamberg J, Perinchief P. Two chromosome aberrations in the child of a woman with systemic lupus erythematosus treated with azathioprine and prednisone. Am J Med Genet 1984; 17:627-632.
60. Haugen G, Fauchald P, Sodal G, et al. Pregnancy outcome in renal allograft recipients in norway: the importance of immunosuppressive drug regimen and health status before pregnancy. Acta Obstet Gynecol Scand 1994; 73:541-546.
61. Radomski JS, Ahlswede BA, Jarrell BE, et al. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transplant Proc 1995; 27:1089-1090.
62. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and antitnf-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108:433-440.
63. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79:696-701.
64. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85:647-654.
65. Nandakumaran M, Eldeen AS. Transfer of cyclosporine in the perfused human placenta. Dev Pharmacol Ther 1990; 15:101-105.
66. Schmid BP. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate or cyclosporin A. Toxicology 1984; 31:9-21.
67. Mason RJ, Thomson AW, Whiting PH, et al. Cyclosporine-induced fetotoxicity in the rat. Transplantation 1985; 39:9-12.
68. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71:1051-1055.
69. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twentyfour-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken) 2013; 65:362-371.